Catalog No.
DHA29105
Host species
Homo sapiens
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-lambda
Applications
Research Grade Biosimilar
Target
TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
O14763
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
HGS-ETR2, CAS: 845816-02-6
Note
For research use only. Not suitable for clinical or therapeutic use.
99m Tc-Labeled lexatumumab, PMID: 20641185
111 In-Labeled lexatumumab, PMID: 20641892
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model, PMID: 17184908
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers, PMID: 17947486
Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner, PMID: 19276256
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels, PMID: 17638911
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib, PMID: 19174554
Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma, PMID: 28459212
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors, PMID: 19633048
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma, PMID: 23029050
Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array, PMID: 22205156
Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2, PMID: 17243490
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors, PMID: 23071222
RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis, PMID: 22927431
Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions, PMID: 19860913
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin, PMID: 17953743
Reactive oxygen species is essential for cycloheximide to sensitize lexatumumab-induced apoptosis in hepatocellular carcinoma cells, PMID: 21347335
111 In-Labeled mapatumumab, PMID: 20641403
99m Tc-Labeled mapatumumab, PMID: 20641397
Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer, PMID: 21653692
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression, PMID: 25724522
Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression, PMID: 17922852
Death receptors as targets in cancer, PMID: 23638798
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells, PMID: 22738917
Gateways to clinical trials, PMID: 17003851
Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma, PMID: 22885470
TRAIL-based therapeutic approaches for the treatment of pediatric malignancies, PMID: 23458616
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis, PMID: 23192275
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5, PMID: 20354842
Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis, PMID: 19788693
TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors, PMID: 20940278
Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells, PMID: 30947287
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors, PMID: 20126991
Gateways to clinical trials, PMID: 20664824
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways, PMID: 24603332
Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20, PMID: 17671142
RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex, PMID: 22890322
Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma, PMID: 22446330
Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis, PMID: 19734228
Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels, PMID: 18483385
Spectral imaging-based methods for quantifying autophagy and apoptosis, PMID: 21757995
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis, PMID: 24086526
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation, PMID: 21653830
A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR, PMID: 19366809
Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin, PMID: 19424623
Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma, PMID: 25344582
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells, PMID: 17292950
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation, PMID: 22895172
Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma, PMID: 20505780
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2, PMID: 17875785
For research use only. Not for human or drug use.
